Effective Market Exclusivity of New Molecular Entities for Rare and Non-rare Diseases-Reference-Cited by-同舟云学术

Effective Market Exclusivity of New Molecular Entities for Rare and Non-rare Diseases

Published:2019-12-20 Issue:1 Volume:34 Page:19-29
ISSN:1178-2595
Container-title:Pharmaceutical Medicine
language:en
Short-container-title:Pharm Med

Author:

Kerr Kirk W.,Glos Lukas J.^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology

Link

http://link.springer.com/content/pdf/10.1007/s40290-019-00317-9.pdf

Reference31 articles.

1. IMS Institute for Human Data Science. Price declines after branded medicines lose exclusivity in the U.S. 2016. https://www.iqvia.com/-/media/iqvia/pdfs/institute-reports/price-declines-after-branded-medicines-lose-exclusivity-in-the-us.pdf?la=en&hash=0AA1C81204DBB674F83DAB7EE2E2BB5EDD2F3030. Accessed 18 Oct 2019.

2. Kesselheim AS, Avorn J, Sarpatwari A. The high cost of prescription drugs in the United States: origins and prospects for reform. JAMA. 2016;316(8):858–71.

3. Kesselheim AS. Using market-exclusivity incentives to promote pharmaceutical innovation. N Engl J Med. 2010;363:1855–62.

4. Grabowski H, Kyle M. Generic competition and market exclusivity periods in pharmaceuticals. Manag Decis Econ. 2007;27:1–12.

5. Grabowski H, Kyle M, Mortimer R, Long G, Kirson N. Evolving brand-name and generic drug competition may warrant a revision of the Hatch-Waxman act. Health Aff. 2011;30(11):2157–66.

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Orphan Drug Label Expansions: Analysis Of Subsequent Rare And Common Indication Approvals;Health Affairs;2024-01-01

2. Exploring the Potential Challenges for Developing Generic Orphan Drugs for Rare Diseases: A Survey of US and European Markets;Value in Health Regional Issues;2023-05

3. Lifecycle management of orphan drugs approved in Japan;Orphanet Journal of Rare Diseases;2022-07-29

4. Analysis of Patent and Regulatory Exclusivity for Novel Agents in China and the United States: A Cohort Study of Drugs Approved Between 2018 and 2021;Clinical Pharmacology & Therapeutics;2022-05-22

5. Risk Assessment of Failures in Generic Drug Development and Approval Procedure under Competitive Generic Drug Therapy and Patent Challenge Exclusivities Provided by the United States Food and Drug Administration;Acta Marisiensis - Seria Medica;2022-03-01